4 Medical Devices Behemoths to Buy Amid Extensive AI Applications

The medical device industry is experiencing significant integration of artificial intelligence, driven by increasing demand for precision and personalized medicine. Four key companies are highlighted for their extensive AI applications: Boston Scientific, leveraging AI in heart diagnostics and imaging; Johnson & Johnson, focusing on AI in robotic surgery and digital analytics; GE HealthCare, advancing AI-powered imaging and precision care; and Tempus AI, which applies AI to personalized patient care and treatment decisions, notably exhibiting high projected growth rates. These firms, all rated Zacks Rank #2 (Buy), are positioned as attractive investment opportunities due to their transformative AI contributions to clinical workflows and patient outcomes.

Analysis

The medical device sector is undergoing a significant transformation driven by the integration of artificial intelligence, a trend fueled by rising demand for precision and personalized medicine. The market presents a spectrum of opportunities, from established large-cap firms to high-growth technology companies. Boston Scientific (BSX) is demonstrating robust momentum, with projected revenue and earnings growth of 18.3% and 18.7% respectively, supported by a 2.4% upward revision in its current-year earnings consensus and strong demand for its AI-enhanced cardiovascular products like HeartLogic and the WATCHMAN line. In contrast, Johnson & Johnson (JNJ) offers a more stable profile, applying AI to its surgical robotics (Ottava) and digital surgery platforms, with more modest expected growth of 5.2% in revenue and 8.8% in earnings. GE HealthCare (GEHC) is capitalizing on increased hospital capital investment, leveraging AI in its imaging and diagnostics portfolio; while its projected revenue and earnings growth are lower at 3.5% and 0.9%, a significant 12.7% upward revision in its earnings consensus suggests strengthening fundamentals. Tempus AI (TEM) represents the high-growth end of the spectrum, with staggering expected revenue and earnings growth of 81.1% and 55.7%, respectively, driven by its focused application of AI to deliver personalized oncology and cardiology treatments. All four companies carry a Zacks Rank #2 (Buy), indicating a bullish analyst outlook on their ability to capitalize on this secular growth trend.

Key Decisions for Investors

• Investors should consider allocating capital to the AI-in-MedTech theme, differentiating between the high-growth, higher-risk profile of Tempus AI and the more stable, established market positions of Johnson & Johnson and Boston Scientific.
• Monitor the magnitude of consensus earnings estimate revisions as a key performance indicator; GE HealthCare's notable 12.7% upward revision warrants particular attention as it may signal accelerating profitability not yet fully reflected in its modest top-line growth forecasts.
• For growth-oriented portfolios, the exceptional projected revenue growth of 81.1% for Tempus AI and 18.3% for Boston Scientific present compelling cases, but require diligence regarding execution and valuation.
• Despite Boston Scientific's strong performance, investors should remain aware of noted macroeconomic risks, such as tariff tensions and cost inflation, which could impact margins across the sector.